Histone deacetylation and motor neuron degeneration

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 3, 2010, Pages 279-284

  Schmalbach, S ^a   Petri, S ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Amyotrophic lateral sclerosis; Hdac inhibitors; Histone deacetylases; Neurodegeneration; Sirtuins; Transcriptional regulation

Indexed keywords

4 PHENYLBUTYRIC ACID; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; PHENYLBUTYRATE; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; DEACETYLATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPINAL MUSCULAR ATROPHY; TRANSCRIPTION REGULATION;

EID: 77954325417     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710791292684     Document Type: Article

References (84)

1. Rosen, D. R.; Siddique, T.; Patterson, D.; Figlewicz, D. A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J. P.; Deng, H. X. Mutations in Cu/Zn superoxide dismutase gene are associated withfamilial amyotrophic lateral sclerosis. Nature, 1993, 362, 59-62.
2. Sreedharan, J.; Blair, I. P.; Tripathi, V. B.; Hu, X.; Vance, C.; Rogelj, B.; Ackerley, S.; Durnall, J. C.; Williams, K. L.; Buratti, E.; Baralle, F.; de Belleroche, J.; Mitchell, J. D.; Leigh, P. N.; AlChalabi, A.; Miller, C. C.; Nicholson, G.; Shaw, C. E. TDP-43mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 2008, 319 (5870), 1668-1672.
3. Vance, C.; Rogelj, B.; Hortobagyi, T.; De Vos, K. J.; Nishimura, A. L.; Sreedharan, J.; Hu, X.; Smith, B.; Ruddy, D.; Wright, P.; Ganesalingam, J.; Williams, K. L.; Tripathi, V.; Al Saraj, S.; AlChalabi, A.; Leigh, P. N.; Blair, I. P.; Nicholson, G.; de Belleroche, J.; Gallo, J. M.; Miller, C. C.; Shaw, C. E. Mutations in FUS, anRNA processing protein, cause familial amyotrophic lateralsclerosis type 6. Science, 2009, 323(5918), 1208-1211.
4. Kwiatkowski, T. J., Jr.; Bosco, D. A.; LeClerc, A. L.; Tamrazian, E.; Vanderburg, C. R.; Russ, C.; Davis, A.; Gilchrist, J.; Kasarskis, E. J.; Munsat, T.; Valdmanis, P.; Rouleau, G. A.; Hosler, B. A.; Cortelli, P.; de Jong, P. J.; Yoshinaga, Y.; Haines, J. L.; Pericak-Vance, M. A.; Yan, J.; Ticozzi, N.; Siddique, T.; McKenna-Yasek, D.; Sapp, P. C.; Horvitz, H. R.; Landers, J. E.; Brown, R. H. Jr. Mutations in the FUS/TLS gene on chromosome 16 cause familialamyotrophic lateral sclerosis. Science, 2009, 323(5918), 1205-1208.
5. Gurney, M. E.; Pu, H.; Chiu, A. Y.; Dal Canto, M. C.; Polchow, C. Y.; Alexander, D. D.; Caliendo, J.; Hentati, A.; Kwon, Y. W.; Deng, H. X.; Chen, W.; Zhai, P.; Sufit, R. L.; Siddique, T. Motorneuron degeneration in mice that express a human Cu, Znsuperoxide dismutase mutation. Science, 1994, 264(5166), 1772-1775.
6. Ripps, M. E.; Huntley, G. W.; Hof, P. R.; Morrison, J. H.; Gordon, J. W. Transgenic mice expressing an altered murine superoxidedismutase gene provide an animal model of amyotrophic lateralsclerosis. Proc. Natl. Acad. Sci. USA, 1995, 92(3), 689-693.
7. Olsen, M. K.; Roberds, S. L.; Ellerbrock, B. R.; Fleck, T. J.; McKinley, D. K.; Gurney, M. E. Disease mechanisms revealed bytranscription profiling in SOD1-G93A transgenic mouse spinalcord. Ann. Neurol., 2001, 50(6), 730-740.
8. Malaspina, A.; de Belleroche, J. Spinal cord molecular profilingprovides a better understanding of amyotrophic lateral sclerosispathogenesis. Brain Res. Brain Res. Rev., 2004, 45(3), 213-229.
9. Ishigaki, S.; Niwa, J.; Ando, Y.; Yoshihara, T.; Sawada, K.; Doyu, M.; Yamamoto, M.; Kato, K.; Yotsumoto, Y.; Sobue, G. Differentially expressed genes in sporadic amyotrophic lateralsclerosis spinal cords-screening by molecular indexing andsubsequent cDNA microarray analysis. FEBS Lett., 2002, 531(2), 354-358.
10. Yoshihara, T.; Ishigaki, S.; Yamamoto, M.; Liang, Y.; Niwa, J.; Takeuchi, H.; Doyu, M.; Sobue, G. Differential expression ofinflammation-and apoptosis-related genes in spinal cords of amutant SOD1 transgenic mouse model of familial amyotrophiclateral sclerosis. J. Neurochem., 2002, 80(1), 158-167.
11. Shabbeer, S.; Carducci, M. A. Focus on deacetylation for the rapeutic benefit. I Drugs, 2005, 8(2), 144-154.
12. Ouaissi, M.; Ouaissi, A. Histone deacetylase enzymes as potentialdrug targets in cancer and parasitic diseases. J. Biomed. Biotechnol., 2006, 2006(2), 13474.
13. Pogo, B. G.; Allfrey, V. G.; Mirsky, A. E. RNA synthesis and histoneacetylation during the course of gene activation in lymphocytes. Proc. Natl. Acad. Sci. USA, 1966, 55(4), 805-812.
14. Grunstein, M. Histone acetylation in chromatin structure andtranscription. Nature, 1997, 389(6649), 349-352.
15. Bernstein, B. E.; Tong, J. K.; Schreiber, S. L. Genomewide studies ofhistone deacetylase function in yeast. Proc. Natl. Acad. Sci. USA, 2000, 97(25), 13708-13713.
16. Luo, J.; Su, F.; Chen, D.; Shiloh, A.; Gu, W. Deacetylation of p53modulates its effect on cell growth and apoptosis. Nature, 2000, 408(6810), 377-381.
17. Chen, L.; Fischle, W.; Verdin, E.; Greene, W. C. Duration ofnuclear NF-kappaB action regulated by reversible acetylation. Science, 2001, 293(5535), 1653-1657.
18. Glozak, M. A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation anddeacetylation of non-histone proteins. Gene, 2005, 363 15-23
19. Saha, R. N.; Pahan, K. HATs and HDACs in neurodegeneration: atale of disconcerted acetylation homeostasis. Cell Death. Differ., 2006, 13(4), 539-550.
20. Rouaux, C.; Loeffler, J. P.; Boutillier, A. L. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy inneurological disorders. Biochem. Pharmacol., 2004, 68(6), 1157-1164.
21. Rouaux, C.; Jokic, N.; Mbebi, C.; Boutillier, S.; Loeffler, J. P.; Boutillier, A. L. Critical loss of CBP/p300 histone acetylase activityby caspase-6 during neurodegeneration. EMBO J., 2003, 22(24), 6537-6549.
22. Fischbeck, K. H. Polyglutamine expansion neurodegenerative disease. Brain Res. Bull., 2001, 56(3-4), 161-163.
23. Steffan, J. S.; Kazantsev, A.; Spasic-Boskovic, O.; Greenwald, M.; Zhu, Y. Z.; Gohler, H.; Wanker, E. E.; Bates, G. P.; Housman, D. E.; Thompson, L. M. The Huntington's disease protein interacts withp53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA, 2000, 97(12), 6763-6768.
24. McCampbell, A.; Taylor, J. P.; Taye, A. A.; Robitschek, J.; Li, M.; Walcott, J.; Merry, D.; Chai, Y.; Paulson, H.; Sobue, G.; Fischbeck, K. H. CREB-binding protein sequestration by expandedpolyglutamine. Hum. Mol. Genet., 2000, 9(14), 2197-2202.
25. Chawla, S.; Vanhoutte, P.; Arnold, F. J.; Huang, C. L.; Bading, H. Neuronal activity-dependent nucleocytoplasmic shuttling ofHDAC4 and HDAC5. J. Neurochem., 2003, 85(1), 151-159.
26. Gao, L.; Cueto, M. A.; Asselbergs, F.; Atadja, P. Cloning andfunctional characterization of HDAC11, a novel member of thehuman histone deacetylase family. J. Biol. Chem., 2002, 277(28), 25748-25755.
27. Gregoretti, I. V.; Lee, Y. M.; Goodson, H. V. Molecular evolution ofthe histone deacetylase family: functional implications ofphylogenetic analysis. J. Mol. Biol., 2004, 338(1), 17-31.
28. Broide, R. S.; Redwine, J. M.; Aftahi, N.; Young, W.; Bloom, F. E.; Winrow, C. J. Distribution of histone deacetylases 1-11 in the ratbrain. J. Mol. Neurosci., 2007, 31(1), 47-58.
29. Salminen, A.; Tapiola, T.; Korhonen, P.; Suuronen, T. Neuronalapoptosis induced by histone deacetylase inhibitors. Brain Res. Mol. Brain Res., 1998, 61(1-2), 203-206.
30. Ragancokova, D.; Jahn, K.; Kotsiari, A.; Schlesinger, F.; Haastert, K.; Stangel, M.; Petri, S.; Krampfl, K. Analysis of neuroprotectiveeffects of valproic acid on primary motor neurons in monocultureor co-cultures with astrocytes or Schwann cells. Cell Mol. Neurobiol., 2009, 29(6-7), 1037-1043.
31. Uo, T.; Veenstra, T. D.; Morrison, R. S. Histone deacetylaseinhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J. Neurosci., 2009, 29(9), 2824-2832.
32. Ito, K.; Hanazawa, T.; Tomita, K.; Barnes, P. J.; Adcock, I. M. Oxidative stress reduces histone deacetylase 2 activity andenhances IL-8 gene expression: role of tyrosine nitration. Biochem. Biophys. Res. Commun., 2004, 315(1), 240-245.
33. Minetti, G. C.; Colussi, C.; Adami, R.; Serra, C.; Mozzetta, C.; Parente, V.; Fortuni, S.; Straino, S.; Sampaolesi, M.; Di Padova, M.; Illi, B.; Gallinari, P.; Steinkuhler, C.; Capogrossi, M. C.; Sartorelli, V.; Bottinelli, R.; Gaetano, C.; Puri, P. L. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med., 2006, 12(10), 1147-1150.
34. Colussi, C.; Mozzetta, C.; Gurtner, A.; Illi, B.; Rosati, J.; Straino, S.; Ragone, G.; Pescatori, M.; Zaccagnini, G.; Antonini, A.; Minetti, G.; Martelli, F.; Piaggio, G.; Gallinari, P.; Steinkuhler, C.; Clementi, E.; Dell'Aversana, C.; Altucci, L.; Mai, A.; Capogrossi, M. C.; Puri, P. L.; Gaetano, C. HDAC2 blockade by nitric oxide andhistone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. USA, 2008, 105(49), 19183-19187.
35. Pandey, U. B.; Nie, Z.; Batlevi, Y.; McCray, B. A.; Ritson, G. P.; Nedelsky, N. B.; Schwartz, S. L.; DiProspero, N. A.; Knight, M. A.; Schuldiner, O.; Padmanabhan, R.; Hild, M.; Berry, D. L.; Garza, D.; Hubbert, C. C.; Yao, T. P.; Baehrecke, E. H.; Taylor, J. P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature, 2007, 447(7146), 859-863.
36. Pandey, U. B.; Batlevi, Y.; Baehrecke, E. H.; Taylor, J. P. HDAC6 atthe intersection of autophagy, the ubiquitin proteasome system and neurodegeneration. Autophagy, 2007, 3(6), 643-645.
37. Dompierre, J. P.; Godin, J. D.; Charrin, B. C.; Cordelieres, F. P.; King, S. J.; Humbert, S.; Saudou, F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington'sdisease by increasing tubulin acetylation. J. Neurosci., 2007, 27(13), 3571-3583.
38. Rivieccio, M. A.; Brochier, C.; Willis, D. E.; Walker, B. A.; D'Annibale, M. A.; McLaughlin, K.; Siddiq, A.; Kozikowski, A. P.; Jaffrey, S. R.; Twiss, J. L.; Ratan, R. R.; Langley, B. HDAC6 is atarget for protection and regeneration following injury in thenervous system. Proc. Natl. Acad. Sci. USA, 2009, 106(46), 19599-19604.
39. Fiesel, F. C.; Voigt, A.; Weber, S. S.; Van den, H. C.; Waldenmaier, A.; Gorner, K.; Walter, M.; Anderson, M. L.; Kern, J. V.; Rasse, T. M.; Schmidt, T.; Springer, W.; Kirchner, R.; Bonin, M.; Neumann, M.; Baekelandt, V.; Alunni-Fabbroni, M.; Schulz, J. B.; Kahle, P. J. Knockdown of transactive response DNA-bindingprotein (TDP-43) downregulates histone deacetylase 6. EMBO J., 2010, 29(1), 209-221.
40. Pallos, J.; Bodai, L.; Lukacsovich, T.; Purcell, J. M.; Steffan, J. S.; Thompson, L. M.; Marsh, J. L. Inhibition of specific HDACs andsirtuins suppresses pathogenesis in a Drosophila model ofHuntington's disease. Hum. Mol. Genet., 2008, 17(23), 3767-3775.
41. Bolger, T. A; Yao, T. P. Intracellular trafficking of histonedeacetylase 4 regulates neuronal cell death. J. Neurosci., 2005, 25(41), 9544-9553.
42. Simpson, C. L.; Lemmens, R.; Miskiewicz, K.; Broom, W. J.; Hansen, V. K.; van Vught, P. W.; Landers, J. E.; Sapp, P.; Van Den, B. L.; Knight, J.; Neale, B. M.; Turner, M. R.; Veldink, J. H.; Ophoff, R. A.; Tripathi, V. B.; Beleza, A.; Shah, M. N.; Proitsi, P.; VanHoecke, A.; Carmeliet, P.; Horvitz, H. R.; Leigh, P. N.; Shaw, C. E.; van den Berg, L. H.; Sham, P. C.; Powell, J. F.; Verstreken, P.; Brown, R. H., Jr.; Robberecht, W.; Al Chalabi, A. Variants of theelongator protein 3 (ELP3) gene are associated with motor neurondegeneration. Hum. Mol. Genet., 2009, 18(3), 472-481.
43. Creppe, C.; Malinouskaya, L.; Volvert, M. L.; Gillard, M.; Close, P.; Malaise, O.; Laguesse, S.; Cornez, I.; Rahmouni, S.; Ormenese, S.; Belachew, S.; Malgrange, B.; Chapelle, J. P.; Siebenlist, U.; Moonen, G.; Chariot, A.; Nguyen, L. Elongator controls themigration and differentiation of cortical neurons throughacetylation of alpha-tubulin. Cell, 2009, 136(3), 551-564.
44. Langley, B.; D'Annibale, M. A.; Suh, K.; Ayoub, I.; Tolhurst, A.; Bastan, B.; Yang, L.; Ko, B.; Fisher, M.; Cho, S.; Beal, M. F.; Ratan, R. R. Pulse inhibition of histone deacetylases inducescomplete resistance to oxidative death in cortical neurons withouttoxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cellcycle-independent neuroprotection. J. Neurosci., 2008, 28(1), 163-176.
45. Gardian, G.; Browne, S. E.; Choi, D. K.; Klivenyi, P.; Gregorio, J.; Kubilus, J. K.; Ryu, H.; Langley, B.; Ratan, R. R.; Ferrante, R. J.; Beal, M. F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem., 2005, 280(1), 556-563.
46. Sleiman, S. F.; Basso, M.; Mahishi, L.; Kozikowski, A. P.; Donohoe, M. E.; Langley, B.; Ratan, R. R. Putting the 'HAT' backon survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opin. Investig. Drugs, 2009, 18(5), 573-584.
47. Langley, B.; Gensert, J. M.; Beal, M. F.; Ratan, R. R. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord., 2005, 4(1), 41-50.
48. Ryu, H.; Smith, K.; Camelo, S. I.; Carreras, I.; Lee, J.; Iglesias, A. H.; Dangond, F.; Cormier, K. A.; Cudkowicz, M. E.; Brown, R. H., Jr.; Ferrante, R. J. Sodium phenylbutyrate prolongs survivaland regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem., 2005, 93(5), 1087-1098.
49. Riccio, A.; Ahn, S.; Davenport, C. M.; Blendy, J. A.; Ginty, D. D. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science, 1999, 286(5448), 2358-2361.
50. Bedogni, B.; Pani, G.; Colavitti, R.; Riccio, A.; Borrello, S.; Murphy, M.; Smith, R.; Eboli, M. L.; Galeotti, T. Redox regulationof cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependentcell survival. J. Biol. Chem., 2003, 278(19), 16510-16519.
51. Tamatani, M.; Che, Y. H.; Matsuzaki, H.; Ogawa, S.; Okado, H.; Miyake, S.; Mizuno, T.; Tohyama, M. Tumor necrosis factorinduces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J. Biol. Chem., 1999, 274(13), 8531-8538.
52. Zhong, L. T.; Sarafian, T.; Kane, D. J.; Charles, A. C.; Mah, S. P.; Edwards, R. H.; Bredesen, D. E. bcl-2 inhibits death of centralneural cells induced by multiple agents. Proc. Natl. Acad. Sci. USA, 1993, 90(10), 4533-4537.
53. Merry, D. E.; Korsmeyer, S. J. Bcl-2 gene family in the nervoussystem. Annu. Rev. Neurosci., 1997, 20, 245-267.
54. Brichta, L.; Hofmann, Y.; Hahnen, E.; Siebzehnrubl, F. A.; Raschke, H.; Blumcke, I.; Eyupoglu, I. Y.; Wirth, B. Valproic acidincreases the SMN2 protein level: a well-known drug as a potentialtherapy for spinal muscular atrophy. Hum. Mol. Genet., 2003, 12(19), 2481-2489.
55. Sugai, F.; Yamamoto, Y.; Miyaguchi, K.; Zhou, Z.; Sumi, H.; Hamasaki, T.; Goto, M.; Sakoda, S. Benefit of valproic acid insuppressing disease progression of ALS model mice. Eur. J. Neurosci., 2004, 20(11), 3179-3183.
56. Weihl, C. C.; Connolly, A. M.; Pestronk, A. Valproate may improvestrength and function in patients with type III/IV spinal muscleatrophy. Neurology, 2006, 67(3), 500-501.
57. Rouaux, C.; Panteleeva, I.; Rene, F.; Gonzalez de Aguilar, J. L.; Echaniz-Laguna, A.; Dupuis, L.; Menger, Y.; Boutillier, A. L.; Loeffler, J. P. Sodium valproate exerts neuroprotective effects invivo through CREB-binding protein-dependent mechanisms butdoes not improve survival in an amyotrophic lateral sclerosismouse model. J. Neurosci., 2007, 27(21), 5535-5545.
58. Gan, L.; Mucke, L. Paths of convergence: sirtuins in aging and neurodegeneration. Neuron, 2008, 58(1), 10-14.
59. Kazantsev, A. G.; Thompson, L. M. Therapeutic application ofhistone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov., 2008, 7(10), 854-868.
60. Outeiro, T. F.; Marques, O.; Kazantsev, A. Therapeutic role ofsirtuins in neurodegenerative disease. Biochim. Biophys. Acta, 2008, 1782(6), 363-369.
61. Vaziri, H.; Dessain, S. K.; Ng, E. E.; Imai, S. I.; Frye, R. A.; Pandita, T. K.; Guarente, L.; Weinberg, R. A. hSIR2(SIRT1) functions as anNAD-dependent p53 deacetylase. Cell, 2001, 107(2), 149-159.
62. Cohen, H. Y.; Lavu, S.; Bitterman, K. J.; Hekking, B.; Imahiyerobo, T. A.; Miller, C.; Frye, R.; Ploegh, H.; Kessler, B. M.; Sinclair, D. A. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell, 2004, 13(5), 627-638.
63. Westphal, C. H.; Dipp, M. A.; Guarente, L. A therapeutic role forsirtuins in diseases of aging? Trends Biochem. Sci., 2007, 32(12), 555-560.
64. Kyrylenko, S.; Kyrylenko, O.; Suuronen, T.; Salminen, A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell Mol. LifeSci., 2003, 60(9), 1990-1997.
65. Kaeberlein, M.; McVey, M.; Guarente, L. The SIR2/3/4 complexand SIR2 alone promote longevity in Saccharomyces cerevisiae bytwo different mechanisms. Genes Dev., 1999, 13(19), 2570-2580.
66. Kim, D.; Nguyen, M. D.; Dobbin, M. M.; Fischer, A.; Sananbenesi, F.; Rodgers, J. T.; Delalle, I.; Baur, J. A.; Sui, G.; Armour, S. M.; Puigserver, P.; Sinclair, D. A.; Tsai, L. H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer'sdisease and amyotrophic lateral sclerosis. EMBO J., 2007, 26(13), 3169-3179.
67. Cohen, H. Y.; Miller, C.; Bitterman, K. J.; Wall, N. R.; Hekking, B.; Kessler, B.; Howitz, K. T.; Gorospe, M.; de Cabo, R.; Sinclair, D. A. Calorie restriction promotes mammalian cell survival by inducingthe SIRT1 deacetylase. Science, 2004, 305(5682), 390-392.
68. Pedersen, W. A.; Mattson, M. P. No benefit of dietary restriction ondisease onset or progression in amyotrophic lateral sclerosis Cu/Zn-superoxide dismutase mutant mice. Brain Res., 1999, 833(1), 117-120.
69. Rodgers, J. T.; Lerin, C.; Haas, W.; Gygi, S. P.; Spiegelman, B. M.; Puigserver, P. Nutrient control of glucose homeostasis through acomplex of PGC-1alpha and SIRT1. Nature, 2005, 434(7029), 113-118.
70. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M., Puigserver, P.; Auwerx, J. Resveratrolimproves mitochondrial function and protects against metabolicdisease by activating SIRT1 and PGC-1alpha. Cell, 2006, 127(6), 1109-1122.
71. Dali-Youcef, N.; Lagouge, M.; Froelich, S.; Koehl, C.; Schoonjans, K.; Auwerx, J. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann. Med., 2007, 39(5), 335-345.
72. Bordone, L.; Motta, M. C.; Picard, F.; Robinson, A.; Jhala, U. S.; Apfeld, J.; McDonagh, T.; Lemieux, M.; McBurney, M.; Szilvasi, A., Easlon, E. J.; Lin, S. J., Guarente, L. Sirt1 regulates insulinsecretion by repressing UCP2 in pancreatic beta cells. PLoS Biol., 2006, 4(2), e31.
73. Pfister, J. A.; Ma, C.; Morrison, B. E.; D'Mello, S. R. Opposingeffects of sirtuins on neuronal survival: SIRT1-mediatedneuroprotection is independent of its deacetylase activity. PLoSOne, 2008, 3(12), e4090.
74. Araki, T.; Sasaki, Y.; Milbrandt, J. Increased nuclear NADbiosynthesis and SIRT1 activation prevent axonal degeneration. Science, 2004, 305(5686), 1010-1013.
75. Parker, J. A.; Arango, M.; Abderrahmane, S.; Lambert, E.; Tourette, C.; Catoire, H.; Neri, C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet., 2005, 37(4), 349-350.
76. Julien, C.; Tremblay, C.; Emond, V.; Lebbadi, M.; Salem, N. Jr.; Bennett, D. A.; Calon, F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2009, 68(1), 48-58.
77. Li, Y.; Xu, W.; McBurney, M. W.; Longo, V. D. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab., 2008, 8(1), 38-48.
78. Ghosh, S.; Feany, M. B. Comparison of pathways controllingtoxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Hum. Mol. Genet., 2004, 13(18), 2011-2018.
79. Dryden, S. C.; Nahhas, F. A.; Nowak, J. E.; Goustin, A. S.; Tainsky, M. A. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol. Cell Biol., 2003, 23(9), 3173-3185.
80. North, B. J.; Verdin, E. Interphase nucleo-cytoplasmic shuttling andlocalization of SIRT2 during mitosis. PLoS One, 2007, 2(8), e784.
81. Suzuki, K.; Koike, T. Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to axonal degeneration in slowWallerian degeneration mice: a crucial role of tubulin deacetylation. Neuroscience, 2007, 147(3), 599-612.
82. Outeiro, T. F.; Kontopoulos, E.; Altmann, S. M.; Kufareva, I.; Strathearn, K. E.; Amore, A. M.; Volk, C. B.; Maxwell, M. M.; Rochet, J. C.; McLean, P. J.; Young, A. B.; Abagyan, R.; Feany, M. B.; Hyman, B. T.; Kazantsev, A. G. Sirtuin 2 inhibitors rescuealpha-synuclein-mediated toxicity in models of Parkinson's disease. Science, 2007, 317(5837), 516-519.
83. Shi, T.; Wang, F.; Stieren, E.; Tong, Q. SIRT3, a mitochondrialsirtuin deacetylase, regulates mitochondrial function andthermogenesis in brown adipocytes. J. Biol. Chem., 2005, 280(14), 13560-13567.
84. Mostoslavsky, R.; Chua, K. F.; Lombard, D. B.; Pang, W. W.; Fischer, M. R.; Gellon, L.; Liu, P.; Mostoslavsky, G.; Franco, S.; Murphy, M. M.; Mills, K. D.; Patel, P.; Hsu, J. T.; Hong, A. L.; Ford, E.; Cheng, H. L.; Kennedy, C.; Nunez, N.; Bronson, R.; Frendewey, D.; Auerbach, W.; Valenzuela, D.; Karow, M.; Hottiger, M. O.; Hursting, S.; Barrett, J. C.; Guarente, L.; Mulligan, R.; Demple, B.; Yancopoulos, G. D.; Alt, F. W. Genomic instability and aging-likephenotype in the absence of mammalian SIRT6. Cell, 2006, 124(2), 315-329.